Celldex Therapeutics Announces Proposed Public Offering of Common Stock
07 Novembre 2023 - 10:01PM
Celldex Therapeutics, Inc. (“Celldex” or the “Company”)
(Nasdaq: CLDX) today announced that it is proposing to offer and
sell, subject to market conditions, shares of its common stock
in an underwritten public offering. Celldex expects to grant the
underwriters a 30-day option to purchase up to an
additional 15% of the shares of common stock offered in
the public offering. All of the shares of common stock are being
offered by the Company. Celldex intends to use the net proceeds
from the offering to continue clinical and preclinical development
of its product candidates, including current and future development
of barzolvolimab, growing its bispecific antibody platform and
clinical candidates, funding ongoing efforts to develop additional
clinical pipeline products and for general corporate purposes. The
final terms of the offering will depend on market and other
conditions at the time of pricing, and there can be no assurance as
to whether or when the offering may be completed, or as to the
actual size or terms of the offering.
Jefferies and Leerink Partners are acting as the joint
book-running managers for the proposed offering.
The securities described above will be offered pursuant to a
shelf registration statement on Form S-3 (File No. 333-275300),
which was previously filed with the Securities and Exchange
Commission (“SEC”) and became automatically effective
on November 3, 2023. A preliminary prospectus supplement and
accompanying base prospectus relating to and describing the terms
of the offering will be filed with the SEC and will be
available on the SEC’s website located at http://www.sec.gov,
copies of which may be obtained, when available, for free by
contacting Jefferies LLC, Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, New York,
NY 10022, by telephone at (877) 821-7388 or by e-mail
at prospectus_department@jefferies.com; or Leerink
Partners LLC, Syndicate Department, 53 State Street, 40th Floor,
Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105 or by
email at syndicate@leerink.com.
The offering will be made only by means of a prospectus. This
press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company leading the
science at the intersection of mast cell biology and the
development of transformative therapeutics for patients. Our
pipeline includes antibody-based therapeutics which have the
ability to engage the human immune system and/or directly affect
critical pathways to improve the lives of patients with severe
inflammatory, allergic and autoimmune and other devastating
diseases.
Forward Looking Statement
This release contains “forward-looking statements” made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These statements are typically preceded by
words such as “believes,” “expects,” “anticipates,” “intends,”
“will,” “may,” “should,” or similar expressions. These
forward-looking statements reflect management’s current knowledge,
assumptions, judgment and expectations regarding future performance
or events. Although management believes that the expectations
reflected in such statements are reasonable, they give no assurance
that such expectations will prove to be correct or that those goals
will be achieved, and you should be aware that actual results could
differ materially from those contained in the forward-looking
statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, risks
associated with market conditions and the satisfaction of customary
closing conditions related to the offering and uncertainties
related to the Company’s expectations regarding the completion,
timing and size of the proposed offering. For a further description
of the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to the Company’s business in general, please
refer to the Company’s prospectus supplement to be filed with the
SEC, and the documents incorporated by reference therein, including
the Company’s Form 10-K for the year ended December 31, 2022 and
Forms 10-Q for the quarters ended March 31, 2023, June 30, 2023 and
September 30, 2023.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You are cautioned not to place
undue reliance on any forward-looking statements, which speak only
as of the date of this release. We have no obligation, and
expressly disclaim any obligation, to update, revise or correct any
of the forward-looking statements, whether as a result of new
information, future events or otherwise.
Company Contact
Sarah CavanaughSenior Vice President, Corporate Affairs &
AdministrationCelldex Therapeutics, Inc.(508)
864-8337scavanaugh@celldex.com
Patrick TillMeru Advisors(484)
788-8560ptill@meruadvisors.com
Grafico Azioni Celldex Therapeutics (NASDAQ:CLDX)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Celldex Therapeutics (NASDAQ:CLDX)
Storico
Da Mag 2023 a Mag 2024